Extraterritorial liability for germline editing services

Introduction

Extraterritorial liability for germline editing services refers to the legal responsibility of individuals, biotechnology companies, medical professionals and research institutions for providing or facilitating human germline gene-editing services across national borders. Germline editing involves modifying genetic material in reproductive cells, embryos or their precursors in ways that may be inherited by future generations.

The issue becomes legally complicated when a service is provided in one country, the research is conducted in another country, or the resulting genetic changes affect individuals living in different jurisdictions. For example, a biotechnology company established in one country may provide genetic editing services to foreign clients in a jurisdiction where such procedures are prohibited.

Extraterritorial liability is therefore concerned with determining which country's laws apply, whether foreign conduct can be prosecuted domestically and how international cooperation can prevent unethical genetic interventions. It involves principles of criminal law, international human rights law, biotechnology regulation, medical negligence and corporate accountability.

Meaning and scope of extraterritorial liability

Extraterritorial liability arises when a state exercises legal authority over conduct occurring partly or entirely outside its territory.

In germline editing, liability may arise in situations such as:

A biotechnology company provides prohibited germline editing services to foreign customers.

Researchers conduct embryo-editing experiments abroad while receiving funding from a domestic institution.

A medical professional facilitates reproductive genetic interventions in another country.

A company markets germline editing technologies internationally without satisfying applicable regulatory requirements.

An organisation conceals safety violations or misleadingly advertises the clinical benefits of genetic interventions.

The central legal question is whether a country can impose criminal, civil or regulatory consequences on persons whose activities have international connections.

Legal principles governing extraterritorial liability

1. Territorial jurisdiction

Under the territoriality principle, a state generally exercises jurisdiction over activities occurring within its geographical boundaries.

For example, if a biotechnology company performs unlawful genetic research within a country, its domestic regulatory authorities may investigate and impose penalties under applicable national legislation.

2. Nationality principle

Under the nationality principle, a country may regulate certain activities undertaken abroad by its citizens or companies incorporated under its laws.

This principle becomes important when domestic biotechnology companies establish research facilities in foreign jurisdictions to avoid restrictions imposed in their home countries.

3. Protective principle

The protective principle allows states to exercise jurisdiction over certain foreign activities that threaten their essential national interests.

In biotechnology, this principle may become relevant where overseas activities threaten public health, national biosecurity or other legally recognised interests.

4. Universal jurisdiction

Universal jurisdiction permits states to prosecute certain internationally recognised serious crimes regardless of where they occurred or the nationality of the individuals involved.

However, there is currently no generally recognised universal-jurisdiction offence specifically covering human germline editing. It would therefore be incorrect to assume that every cross-border germline editing violation can be prosecuted under universal jurisdiction.

International legal framework

1. UNESCO Universal Declaration on the Human Genome and Human Rights, 1997

The Declaration recognises the human genome as a fundamental part of the common heritage of humanity.

Article 11 states that practices contrary to human dignity, such as reproductive human cloning, should not be permitted.

Article 24 assigns UNESCO's International Bioethics Committee an important role in identifying practices that may conflict with human dignity.

Although the Declaration is not legally binding, it provides significant ethical guidance for national biotechnology regulation.

2. Oviedo Convention, 1997

The Convention on Human Rights and Biomedicine establishes important safeguards concerning human rights and biomedical research.

Article 13 permits interventions seeking to modify the human genome only for preventive, diagnostic or therapeutic purposes and only where they do not aim to introduce modifications in the genome of descendants.

Article 18 addresses research on embryos in vitro and establishes additional safeguards.

The Convention is particularly important because it establishes a clear international legal restriction on heritable genetic modifications for its parties.

3. International Covenant on Economic, Social and Cultural Rights, 1966

Article 15 recognises the right to enjoy the benefits of scientific progress and its applications.

It also supports the protection of scientific freedom and the ethical responsibilities associated with scientific research.

In germline editing, this framework highlights the need to balance scientific advancement with human rights and public welfare.

4. Convention on Biological Diversity, 1992

The Convention addresses biodiversity protection and the regulation of biological resources.

Its Cartagena Protocol on Biosafety, 2000, establishes rules concerning the transboundary movement of living modified organisms.

However, its application to human germline editing must be distinguished from its application to genetically modified plants, animals and microorganisms. Human genetic interventions are not automatically governed by the Protocol merely because they involve genetic modification.

Extraterritorial liability under national laws

1. United States

The United States regulates several aspects of human genetic research through federal legislation and regulatory agencies.

The Consolidated Appropriations Act, 2016, included restrictions preventing the FDA from accepting certain applications involving research in which a human embryo is intentionally created or modified to include a heritable genetic modification.

The United States may also apply criminal and civil laws to foreign conduct where statutory jurisdictional requirements are satisfied.

Corporate responsibility may arise from violations of applicable federal regulations, research funding conditions and consumer protection laws.

2. United Kingdom

The Human Fertilisation and Embryology Act, 1990, as amended, establishes a strict regulatory framework for embryo research and reproductive technologies.

The Human Fertilisation and Embryology Authority (HFEA) regulates licensed activities involving human embryos.

The legislation restricts genetic modification of embryos for reproductive purposes. However, the precise reach of British law over activities conducted entirely abroad depends on the applicable statutory provisions and jurisdictional rules.

3. India

India regulates genetic research through several legal and regulatory instruments.

The Environment (Protection) Act, 1986, and the Rules, 1989, establish controls over genetically engineered organisms and related activities.

The Department of Biotechnology and Indian Council of Medical Research guidelines also provide ethical requirements for human biomedical and genetic research.

The Assisted Reproductive Technology (Regulation) Act, 2021, regulates assisted reproductive technology services and associated institutions.

Indian authorities may exercise jurisdiction over relevant domestic conduct and certain foreign conduct where statutory provisions establish such jurisdiction. However, Indian law should not be interpreted as automatically imposing criminal liability on every Indian company for all germline editing activities performed abroad.

Important case laws

There are very few judicial decisions directly addressing extraterritorial liability for human germline editing. Nevertheless, the following cases establish important principles concerning biotechnology, corporate responsibility, medical ethics and international jurisdiction.

1. R (Quintavalle) v. Secretary of State for Health (2003)

The House of Lords examined whether embryos created through cell nuclear replacement technology were covered by the definition of embryos under the Human Fertilisation and Embryology Act, 1990.

The Court adopted an interpretation that accommodated scientific developments within the existing statutory framework.

Legal significance: The judgment demonstrates that biotechnology legislation must be interpreted in light of scientific developments. It is relevant to determining the regulatory status of emerging genetic technologies.

2. Brüstle v. Greenpeace eV (2011)

The Court of Justice of the European Union examined the meaning of a human embryo under European biotechnology patent law.

The Court adopted a broad interpretation of the concept of a human embryo for the purposes of the relevant patent exclusion.

Legal significance: The decision illustrates the importance of ethical considerations in regulating biotechnology and determining the limits of commercial exploitation of human embryonic research.

3. Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

The Supreme Court of India examined disputes involving Monsanto's Bt cotton technology and licensing arrangements with Indian seed companies.

The case primarily concerned patent law and the legal protection of genetically modified agricultural technology.

Legal significance: Although unrelated directly to human germline editing, it demonstrates how biotechnology companies may be held accountable under domestic intellectual property and commercial laws.

4. United States v. Aluminium Company of America (Alcoa) (1945)

The United States Court of Appeals for the Second Circuit considered the application of American antitrust law to foreign conduct affecting domestic commerce.

The decision is associated with the effects doctrine, under which certain foreign conduct may fall within domestic regulatory jurisdiction when it has relevant effects within the country.

Legal significance: The decision provides a general jurisdictional principle that may be relevant when examining foreign biotechnology services that produce legally significant effects within another country's territory. It does not itself establish jurisdiction over germline editing.

Corporate and professional liability

Biotechnology companies and medical professionals may face different forms of liability depending on their conduct and the applicable national laws.

1. Criminal liability: May arise where prohibited genetic interventions, fraud, unlawful embryo research or other criminal offences are established under applicable legislation.

2. Civil liability: Individuals may seek compensation where negligent medical procedures, misleading representations or legally actionable harm are established.

3. Corporate liability: Companies may face penalties where their employees, directors or authorised representatives violate applicable statutory requirements.

4. Professional liability: Medical professionals and researchers may face disciplinary proceedings for violating professional standards, ethical guidelines or licensing conditions.

5. Regulatory liability: Research institutions may lose licences, research approvals or funding where they breach applicable regulatory requirements.

Challenges in enforcing extraterritorial liability

Several difficulties affect the enforcement of laws governing international germline editing services.

Differences in national legislation: Countries follow different approaches to germline editing, creating regulatory gaps.

Jurisdictional conflicts: It may be difficult to determine which country has authority over cross-border activities.

Corporate relocation: Biotechnology companies may move research operations to countries with less restrictive regulatory frameworks.

Evidence collection: Obtaining scientific records, consent documents and research data from foreign jurisdictions can be difficult.

Lack of international consensus: There is no comprehensive, universally binding treaty specifically establishing extraterritorial criminal liability for human germline editing.

Corporate accountability: Complex international corporate structures may make it difficult to identify the persons responsible for unlawful activities.

Conclusion

Extraterritorial liability for germline editing services is an emerging area of biotechnology law that raises complex questions concerning international jurisdiction, corporate accountability, human rights and scientific responsibility.

International instruments such as the UNESCO Universal Declaration on the Human Genome and Human Rights and the Oviedo Convention provide important ethical and legal foundations. National legislation in countries such as India, the United States and the United Kingdom establishes additional safeguards concerning genetic research and reproductive technologies.

Judicial decisions such as R (Quintavalle) v. Secretary of State for Health and Brüstle v. Greenpeace demonstrate how courts address emerging biotechnology issues through existing legal principles.

Ultimately, effective regulation requires international cooperation, transparent corporate governance, enforceable national legislation and clear rules governing cross-border biotechnology services. Such measures are essential to prevent regulatory evasion while ensuring that scientific innovation remains consistent with human dignity, public safety and fundamental rights.